PAVmed Inc. (PAVM) Key Metrics
PAVM valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $19.3M
- Enterprise value
- $49.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 172.1
- Price / book
- 1.0
- EV / EBITDA
- 25.8
- Dividend yield
- —
- Beta
- 0.70
PAVM key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPAVM returns How much profit the business earns on the capital it uses.
Return on equity
2.5%
2025 · hover or tap a bar for each year
20162025
Return on assets−123.6 pts
1.2%
2025 · hover or tap a bar for each year
20162025
Asset turnover−97.8%
0.00
2025 · hover or tap a bar for each year
20162025
PAVM financial health Debt, liquidity and how easily interest is covered.
Debt / equity
0.39
2025 · hover or tap a bar for each year
20162025
Net debt−$18.9M
$11.8M
2025 · hover or tap a bar for each year
20162025
Current ratio+182.3%
0.17
2025 · hover or tap a bar for each year
20162025
Debt / assets−66.9%
0.34
2025 · hover or tap a bar for each year
20162025
PAVM efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+80 days
85 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+261 days
285 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+680 days
754 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−339 days
-384 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+41.8 pts
43.7%
2025 · hover or tap a bar for each year
20162025
PAVM valuation history
Fiscal year-endToday10-year median
PAVM returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PAVM debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PAVM cash returned to shareholders
DividendsBuybacksFree cash flow
PAVM price vs earnings per share
Share price at year-endEPS (right axis)
PAVM key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | $41.0M | — | — | — | — | — | — | $11.96B | — |
| Enterprise value | — | $71.6M | — | — | — | — | — | — | $11.97B | — |
| P/E ratio | — | 1.0 | — | — | — | — | — | — | — | — |
| Price / sales | — | 13.7 | — | — | — | — | — | — | — | — |
| EV / sales | — | 23.9 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | 2.4 | — | — | — | — | — | — | — | — |
| Earnings yield | — | 97.1% | — | — | — | — | — | — | −0.1% | — |
| Free cash flow yield | — | −82.0% | — | — | — | — | — | — | −0.1% | — |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | — | — | — | — | — | — | 0.0% | — |
| Share price at fiscal year-end | $6.62 | $18.82 | $106.53 | $186.16 | $954.13 | $822.28 | $465.44 | $373.14 | $886.41 | $2,676.28 |
| Per share | ||||||||||
| Revenue per share | — | $1.38 | — | — | — | — | — | — | $0.00 | — |
| Earnings per share | — | $18.28 | — | — | — | — | — | — | −$0.71 | — |
| Operating cash flow per share | — | −$15.42 | — | — | — | — | — | — | −$0.49 | — |
| Free cash flow per share | — | −$15.44 | — | — | — | — | — | — | −$0.49 | — |
| Cash per share | — | $0.54 | — | — | — | — | — | — | $0.11 | — |
| Book value per share | — | −$1.15 | — | — | — | — | — | — | −$0.21 | — |
| Tangible book value per share | — | −$1.15 | — | — | — | — | — | — | −$0.21 | — |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | — |
| Capex per share | — | $0.03 | — | — | — | — | — | — | $0.00 | — |
| Debt per share | — | $14.64 | — | — | — | — | — | — | $0.29 | — |
| Shares outstanding | — | 2.2M | — | — | — | — | — | — | 13.5M | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 2.5% | — | — | — | −158.4% | — | — | — | — | — |
| Return on invested capital (ROIC) | −46.6% | — | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | 1.2% | 124.8% | −147.4% | −126.3% | −94.3% | −253.7% | −202.5% | −354.5% | −758.5% | −542.2% |
| Return on tangible assets | 1.0% | 129.8% | −202.5% | −176.1% | −2.4% | −173.3% | −220.0% | −211.5% | −580.6% | −649.2% |
| Income quality (OCF / net income) | — | −0.84 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $13.3M | $31.9M | $48.7M | $36.6M | — | $15.0M | $8.1M | $7.9M | $3.9M | $0 |
| Cash & short-term investments | $1.5M | $1.2M | $19.6M | $42.7M | $79.2M | $17.5M | $6.2M | $8.2M | $1.5M | $585,680 |
| Net debt | $11.8M | $30.7M | $29.1M | −$6.1M | −$79.2M | −$2.6M | $1.9M | −$319,119 | $2.4M | −$585,680 |
| Debt / equity | 0.39 | — | — | — | — | 7.89 | — | — | — | — |
| Debt / assets | 0.34 | 1.04 | 1.47 | 0.68 | — | 0.76 | 1.12 | 0.93 | 2.37 | 0.00 |
| Net debt / EBITDA | — | 1.03 | — | — | — | — | — | — | — | — |
| Current ratio | 0.17 | 0.06 | 0.45 | 1.07 | 10.93 | 0.94 | 0.55 | 0.77 | 0.64 | 0.62 |
| Quick ratio | 0.16 | 0.05 | 0.44 | 1.06 | 10.86 | 0.89 | 0.55 | 0.77 | 0.64 | 0.62 |
| Interest coverage | — | -988.6 | -116.8 | -71.1 | -9.4 | -440.6 | -437.6 | -4.4 | -11.1 | — |
| Working capital | −$12.3M | −$33.3M | −$29.7M | $2.7M | $75.1M | −$1.3M | −$5.3M | −$2.5M | −$920,280 | −$448,316 |
| Invested capital | $45.8M | $28.2M | −$24.7M | −$15.8M | −$17.6M | −$662,000 | −$1.9M | −$2.6M | −$494,841 | −$904,747 |
| Tangible asset value | $22.3M | −$7.0M | −$25.4M | $7.5M | $2.10B | −$473,000 | −$4.6M | −$2.5M | −$2.8M | −$319,067 |
| Net current asset value | −$14.0M | −$35.5M | −$32.6M | $880,000 | $75.1M | −$1.3M | −$5.3M | −$2.5M | −$2.9M | −$448,316 |
| Graham net-net per share | — | −$16.71 | — | — | — | — | — | — | −$0.22 | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $12.55B | $35.2M | $436.0M | $357,000 | $67.44B | $7,099 | $7,099 | $7,099 |
| Share buybacks (net) | — | $0 | $0 | $366,000 | $0 | $0 | $0 | $0 | $388,628 | $0 |
| Capex / revenue | 43.7% | 1.8% | 9.9% | 408.5% | 293.8% | — | — | — | — | — |
| Capex / depreciation | 0.30 | 0.05 | 0.08 | 0.63 | 6.50 | 2.39 | 1.91 | 2.72 | 0.75 | 5.75 |
| Stock-based compensation / revenue | 2,404,225.4% | 215.3% | 454.3% | 5,180.9% | 3,001.8% | — | — | — | — | — |
| R&D / revenue | 6,326,760.6% | 198.1% | 582.2% | 6,721.0% | 3,969.4% | — | — | — | — | — |
| SG&A / revenue | 22,887,323.9% | 1,207.0% | 1,979.2% | 16,108.2% | 6,863.0% | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 84.8 | 4.8 | 5.8 | 105.0 | 73.0 | — | — | — | — | — |
| Days of inventory on hand | 285.3 | 24.3 | 22.7 | 39.7 | 430.8 | 13,568.5 | — | — | — | — |
| Days payables outstanding | 754.3 | 73.8 | 127.6 | 303.1 | 1,954.5 | 42,203.6 | 52,490.2 | 48,528.3 | 46,557.2 | 53,635.4 |
| Cash conversion cycle (days) | -384.1 | -44.7 | -99.1 | -158.4 | -1,450.6 | — | — | — | — | — |
| Receivables turnover | 4.30 | 75.82 | 62.87 | 3.47 | 5.00 | 0.00 | — | — | — | — |
| Payables turnover | 0.48 | 4.94 | 2.86 | 1.20 | 0.19 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventory turnover | 1.28 | 15.00 | 16.05 | 9.18 | 0.85 | 0.03 | — | — | — | — |
| Asset turnover | 0.00 | 0.09 | 0.06 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $16,500 | $39,500 | $39,000 | $108,500 | $100,000 | $1 | — | — | — | — |
| Average payables | $667,500 | $1.2M | $2.2M | $3.0M | $3.1M | $2.7M | $2.0M | $1.3M | $906,909 | $557,367 |
| Average inventory | $252,500 | $402,500 | $400,000 | $393,500 | $690,500 | $855,000 | — | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 4.3% | 6.4% | −2,328.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PAVM's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PAVM valuation and financial ratios
PAVmed earned a return on equity of 2.5% and a return on invested capital of −46.6% in fiscal 2025. It ended the year with $13.3 million of debt and $1.5 million in cash and short-term investments, net debt of $11.8 million.
See the PAVM income statement, the PAVM chart for price history, or the PAVM stock overview for the latest quote and news.
PAVM key metrics FAQ
What is PAVmed's return on equity?
PAVmed's return on equity (ROE) was 2.5% in fiscal 2025: net income of $0.4 million on average shareholders' equity of $15.7 million.
What is PAVmed's ROIC?
PAVmed's return on invested capital was −46.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does PAVmed have?
PAVmed had total debt of $13.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.39.
What is PAVmed's current ratio?
PAVmed's current ratio was 0.17 at the end of fiscal 2025: current assets were 0.17 times current liabilities.